MTAP deficiency leads to epigenetic reprogramming, promotes the formation of glioma stem-like cells, increases PROM1/CD133 expression and tumor incidence, and is associated with poor patient prognosis (49). This evidence concerns the gene PROM1 and central nervous system cancer.